EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.

MLA

Semmlinger, Anna, et al. “EP3 (Prostaglandin E2 Receptor 3) Expression Is a Prognostic Factor for Progression-Free and Overall Survival in Sporadic Breast Cancer.” BMC Cancer, vol. 18, no. 1, Apr. 2018, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s12885-018-4286-9.

APA

Semmlinger, A., von Schoenfeldt, V., Wolf, V., Meuter, A., Kolben, T. M., Kolben, T., Zeder-Goess, C., Weis, F., Gallwas, J., Wuerstlein, R., Hermelink, K., Schmoeckel, E., Harbeck, N., Mayr, D., Mahner, S., Jeschke, U., & Ditsch, N. (2018). EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer. BMC Cancer, 18(1), 1–9. https://doi.org/10.1186/s12885-018-4286-9

Chicago

Semmlinger, Anna, Viktoria von Schoenfeldt, Verena Wolf, Alexandra Meuter, Theresa Maria Kolben, Thomas Kolben, Christine Zeder-Goess, et al. 2018. “EP3 (Prostaglandin E2 Receptor 3) Expression Is a Prognostic Factor for Progression-Free and Overall Survival in Sporadic Breast Cancer.” BMC Cancer 18 (1): 1–9. doi:10.1186/s12885-018-4286-9.